BG65519B1 - Белтъци, свързващи интерлевкин-18, тяхното получаване и приложение - Google Patents

Белтъци, свързващи интерлевкин-18, тяхното получаване и приложение Download PDF

Info

Publication number
BG65519B1
BG65519B1 BG104149A BG10414900A BG65519B1 BG 65519 B1 BG65519 B1 BG 65519B1 BG 104149 A BG104149 A BG 104149A BG 10414900 A BG10414900 A BG 10414900A BG 65519 B1 BG65519 B1 BG 65519B1
Authority
BG
Bulgaria
Prior art keywords
antibody
dna
protein
pharmaceutical composition
viral
Prior art date
Application number
BG104149A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG104149A (bg
Inventor
Ddniela Novick
Charles Dinarello
Menachem Rubinstein
Soo Kim
Original Assignee
Yeda Research And Development Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL12155497A external-priority patent/IL121554A0/xx
Priority claimed from IL12163997A external-priority patent/IL121639A0/xx
Application filed by Yeda Research And Development Co. Ltd. filed Critical Yeda Research And Development Co. Ltd.
Publication of BG104149A publication Critical patent/BG104149A/xx
Publication of BG65519B1 publication Critical patent/BG65519B1/bg

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82Proteins from microorganisms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82Proteins from microorganisms
    • Y10S530/826Viruses
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827Proteins from mammals or birds
    • Y10S530/834Urine; urinary system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
BG104149A 1997-08-14 2000-02-10 Белтъци, свързващи интерлевкин-18, тяхното получаване и приложение BG65519B1 (bg)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IL12155497A IL121554A0 (en) 1997-08-14 1997-08-14 Interleukin-18 binding proteins their preparation and use
IL12163997A IL121639A0 (en) 1997-08-14 1997-08-27 Interleukin-18 binding proteins their preparation and use
IL12186097A IL121860A0 (en) 1997-08-14 1997-09-29 Interleukin-18 binding proteins their preparation and use
IL12213497A IL122134A0 (en) 1997-08-14 1997-11-06 Interleukin-18 binding proteins their preparation and use
IL12546398A IL125463A0 (en) 1997-08-14 1998-07-22 Interleukin-18 binding proteins their preparation and use

Publications (2)

Publication Number Publication Date
BG104149A BG104149A (bg) 2000-08-31
BG65519B1 true BG65519B1 (bg) 2008-10-31

Family

ID=27517687

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104149A BG65519B1 (bg) 1997-08-14 2000-02-10 Белтъци, свързващи интерлевкин-18, тяхното получаване и приложение

Country Status (28)

Country Link
US (4) US6605280B1 (OSRAM)
EP (1) EP1003781B1 (OSRAM)
JP (1) JP4272348B2 (OSRAM)
KR (1) KR100687388B1 (OSRAM)
CN (1) CN1243021C (OSRAM)
AR (2) AR013422A1 (OSRAM)
AT (1) ATE443719T1 (OSRAM)
AU (1) AU755794B2 (OSRAM)
BG (1) BG65519B1 (OSRAM)
BR (1) BRPI9811940B8 (OSRAM)
CA (1) CA2298855C (OSRAM)
CY (1) CY1109664T1 (OSRAM)
CZ (1) CZ300818B6 (OSRAM)
DE (2) DE69841175D1 (OSRAM)
DK (1) DK1003781T3 (OSRAM)
EA (1) EA003675B1 (OSRAM)
EE (1) EE05538B1 (OSRAM)
ES (1) ES2149149T3 (OSRAM)
HU (1) HU226698B1 (OSRAM)
IL (5) IL121860A0 (OSRAM)
NO (1) NO327240B1 (OSRAM)
NZ (1) NZ502392A (OSRAM)
PL (1) PL206070B1 (OSRAM)
PT (1) PT1003781E (OSRAM)
SI (1) SI1003781T1 (OSRAM)
SK (1) SK287194B6 (OSRAM)
UA (1) UA75862C2 (OSRAM)
WO (1) WO1999009063A1 (OSRAM)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393663B2 (en) * 1997-08-01 2008-07-01 Serono Genetics Institute S.A. Expressed sequence tags and encoded human proteins
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
CA2340579A1 (en) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
AR022952A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
IL131047A0 (en) * 1999-07-22 2001-01-28 Yeda Res & Dev Use of il-18 inhibitors
DE60041432D1 (de) * 1999-11-16 2009-03-12 Hayashibara Biochem Lab Antikörper spezifisch für den Interleukin-18 Vorläufer
KR20120011898A (ko) * 2000-02-10 2012-02-08 아보트 러보러터리즈 사람 인터류킨-18에 결합하는 항체 및 이를 제조하고 사용하는 방법
HRP20020652A2 (en) * 2000-02-21 2004-12-31 Applied Research Systems Use of il-18 inhibitors
ATE395075T1 (de) * 2000-05-05 2008-05-15 Serono Lab Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose
AU2005211606B2 (en) * 2000-05-05 2007-02-22 Inserm - Institut National De La Sante Et De La Recherche Medicale Use of IL-18 inhibitors for the treatment and/or prevention of atherosclerosis
AU2002211744B8 (en) 2000-10-11 2008-03-20 Viron Therapeutics, Inc. Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) * 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
ES2295332T3 (es) * 2001-01-29 2008-04-16 Laboratoires Serono Sa Uso de inhibidores de il-18 para el tratamiento y/o prevencion de cardiopatias.
CA2446942C (en) * 2001-05-16 2010-07-20 Yeda Research And Development Co., Ltd. Use of il-18 inhibitors for the treatment or prevention of sepsis
US7655616B2 (en) * 2001-05-25 2010-02-02 Ares Trading S.A. Use of IL-18 inhibitors for treating head injuries
PT2270052T (pt) 2001-06-26 2018-07-04 Amgen Fremont Inc Anticorpos contra opgl
UA78516C2 (en) * 2001-08-10 2007-04-10 Applied Research Systems Use of inhibitors of il-18 for treatment and/or prevention of hypersensitivity disorders, and in particular of delayed-type hypersensitivity
CA2478855C (en) * 2002-03-22 2013-12-17 Applied Research Systems Ars Holding N.V. Use of il-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases
EP1545578A4 (en) 2002-08-28 2010-07-07 Immunex Corp COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASES
EP1572291B1 (en) * 2002-10-08 2013-04-03 Ares Trading S.A. The use of cytokine able to bind il-18bp and of inhibiting the activity of a second cytokine
IL152232A0 (en) * 2002-10-10 2003-05-29 Yeda Res & Dev Promoter to il-18bp, its preparation and use
EP1621616A4 (en) 2003-04-30 2007-07-04 Japan Science & Tech Agency HUMAN ANTI-HUMAN INTERLEUKIN-18 ANTIBODY, FRAGMENT AND METHOD FOR THEIR USE
ES2384241T3 (es) * 2003-05-13 2012-07-02 Merck Serono Sa Variantes activas de la proteína que fija IL-18 y usos médicos de las mismas
JP4741504B2 (ja) 2003-11-05 2011-08-03 アレス トレーディング ソシエテ アノニム Il−18結合タンパク質の精製方法
AU2004290049B2 (en) * 2003-11-12 2011-09-29 The Regents Of The University Of Colorado Compositions and methods for regulation of tumor necrosis factor-alpha
US20050100965A1 (en) * 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
IL159670A0 (en) * 2003-12-31 2004-06-01 Yeda Res & Dev Use of il-18 binding protein in inflammations
WO2005083058A1 (en) * 2004-03-01 2005-09-09 Ares Trading S.A. Use of a serum-free cell culture medium for the production of il-18bp in mammalian cells
WO2005097998A2 (en) * 2004-03-31 2005-10-20 Regeneron Pharmaceuticals, Inc. Il-18 specific polypeptides and therapeutic uses thereof
DE602005009827D1 (de) 2004-06-29 2008-10-30 Ares Trading Sa Verfahren zur aufreinigung von il-18-bindendem protein
EP2267024B1 (en) * 2005-06-03 2012-05-09 Ares Trading S.A. Production of recombinant Il-18 binding protein
ES2376534T3 (es) 2005-06-03 2012-03-14 Merck Serono Sa Uso de isoformas de il-18bp para el tratamiento y/o prevención de enfermedades inflamatorias neurológicas.
CA2610804C (en) * 2005-06-10 2013-11-19 Ares Trading S.A. Process for the purification of il-18 binding protein
CN101003812B (zh) * 2006-01-17 2011-01-05 温州医学院 一种用于制备重组人egf-il18融合蛋白的方法
EP2027157B1 (en) 2006-05-25 2014-08-06 Glaxo Group Limited Modified humanised anti-interleukin-18 antibodies
WO2010040736A2 (en) * 2008-10-07 2010-04-15 Ablynx Nv Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling
EP2941310A4 (en) * 2013-01-02 2016-08-24 Wilsa Inc METHOD AND DEVICE FOR CONDITIONING LIQUIDS
EP3041864B1 (en) * 2013-09-05 2021-07-21 AB2 Bio SA Il-18 binding protein (il-18bp) in inflammatory diseases
US10882905B2 (en) 2015-03-05 2021-01-05 Ab2 Bio Sa IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases
EP3943097A1 (en) 2020-07-24 2022-01-26 AB2 Bio SA Car-t cell therapy
CN120737196A (zh) * 2022-01-28 2025-10-03 和径医药科技(上海)有限公司 一种靶向il-18bp的抗体及其应用
CR20240379A (es) * 2022-03-15 2024-12-11 Compugen Ltd Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia combinada en el tratamiento del cáncer
CN114605521A (zh) * 2022-04-06 2022-06-10 内蒙古农业大学 一种细胞免疫调节蛋白及其应用
CN114891125B (zh) * 2022-06-16 2023-04-11 广东医科大学 一种长效重组白细胞介素-18结合蛋白及其生产方法与应用
CN120530131A (zh) 2023-01-06 2025-08-22 拉森医疗公司 抗il-18bp抗体
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Il—18bp拮抗抗體及其於癌症治療之單一療法及組合療法的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
GB9214857D0 (en) * 1992-07-13 1992-08-26 Medical Res Council Human nucleic acid fragments and their use
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US5776731A (en) 1996-02-21 1998-07-07 Immunex Corporation DNA encoding type-I interleukin-I receptor-like protein designated 2F1
WO1998022137A1 (en) 1996-11-15 1998-05-28 The Kennedy Institute Of Rheumatology SUPPRESSION OF TNF α AND IL-12 IN THERAPY
JP4094066B2 (ja) 1996-12-06 2008-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド インターロイキン−1β変換酵素のインヒビター
US7141393B2 (en) 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
US6087116A (en) 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
IL131815A0 (en) 1997-03-18 2001-03-19 Basf Ag Methods and compositions for modulating responsiveness to corticosteroids
DE69842099D1 (de) 1997-08-01 2011-02-24 Merck Serono Biodevelopment 5' ESTs für sekretierte Proteine, die in verschiedenen Geweben exprimiert werden
AU8555698A (en) 1997-08-01 1999-02-22 Genset 5' ests for secreted proteins expressed in various tissues
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
PL196533B1 (pl) 1998-04-28 2008-01-31 Applied Research Systems Sposób stopniowego przyłączania ugrupowań poli (glikolu etylenowego) (PEG) szeregowo do polipeptydu
CA2276216A1 (en) 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
CA2340579A1 (en) 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
AR022952A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
WO2001003719A2 (en) 1999-07-09 2001-01-18 Amgen Inc. Combination therapy for conditions leading to bone loss
WO2001019373A2 (en) 1999-09-17 2001-03-22 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids

Also Published As

Publication number Publication date
SI1003781T1 (sl) 2009-12-31
NO327240B1 (no) 2009-05-18
AU8746098A (en) 1999-03-08
CN1267307A (zh) 2000-09-20
CZ300818B6 (cs) 2009-08-19
US20060154294A1 (en) 2006-07-13
BRPI9811940A (pt) 2000-09-05
PT1003781E (pt) 2009-10-26
SK287194B6 (sk) 2010-03-08
ES2149149T3 (es) 2009-12-01
CZ2000490A3 (cs) 2000-08-16
AR013422A1 (es) 2000-12-27
WO1999009063A1 (en) 1999-02-25
DE69841175D1 (de) 2009-11-05
CA2298855C (en) 2014-05-27
UA75862C2 (uk) 2006-06-15
US7101689B2 (en) 2006-09-05
DE1003781T1 (de) 2001-01-11
ES2149149T1 (es) 2000-11-01
NO20000700D0 (no) 2000-02-11
EA200000216A1 (ru) 2000-08-28
IL121860A0 (en) 1998-02-22
PL206070B1 (pl) 2010-06-30
AR062867A2 (es) 2008-12-10
IL134523A (en) 2011-09-27
US20040037829A1 (en) 2004-02-26
EA003675B1 (ru) 2003-08-28
KR100687388B1 (ko) 2007-02-26
IL134523A0 (en) 2001-04-30
ATE443719T1 (de) 2009-10-15
IL125463A0 (en) 1999-03-12
SK1762000A3 (en) 2000-09-12
NO20000700L (no) 2000-04-14
PL338647A1 (en) 2000-11-06
US20100010200A1 (en) 2010-01-14
DK1003781T3 (da) 2010-01-25
CN1243021C (zh) 2006-02-22
EE05538B1 (et) 2012-04-16
US6605280B1 (en) 2003-08-12
CA2298855A1 (en) 1999-02-25
HU226698B1 (en) 2009-07-28
CY1109664T1 (el) 2014-08-13
NZ502392A (en) 2002-12-20
EE200000073A (OSRAM) 2000-10-16
BRPI9811940B1 (pt) 2011-10-04
JP4272348B2 (ja) 2009-06-03
IL122134A0 (en) 1998-04-05
EP1003781A1 (en) 2000-05-31
JP2001514876A (ja) 2001-09-18
KR20010022900A (ko) 2001-03-26
US8436148B2 (en) 2013-05-07
HK1028773A1 (en) 2001-03-02
US7799541B2 (en) 2010-09-21
EP1003781B1 (en) 2009-09-23
HUP0003533A2 (hu) 2001-01-29
BG104149A (bg) 2000-08-31
BRPI9811940B8 (pt) 2021-07-06
AU755794B2 (en) 2002-12-19
HUP0003533A3 (en) 2003-08-28

Similar Documents

Publication Publication Date Title
AU755794B2 (en) Interleukin-18 binding proteins, their preparation and use
AU743490B2 (en) NTN-2 member of TNF ligand family
EP0991759A1 (en) Ntn-2 member of tnf ligand family
JPH11507205A (ja) ヒト腫瘍壊死因子受容体
US7696154B2 (en) Methods for treating interleukin-18 mediated disorders with interleukin-18 binding proteins
JP2001157593A (ja) 哺乳動物ケモカインccf18およびレセプターcckr3
EP1019502A2 (en) Human orphan receptor ntr-1
JPH10234385A (ja) 新規ヒトets科メンバーのelf3
JP2005200422A (ja) インターフェロンα/β結合タンパク質およびその製造法
AU2003200442B2 (en) Interleukin-18 binding proteins, their preparation and use
MXPA00001524A (en) Interleukin-18 binding proteins, their preparation and use